Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 9/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.55 |
| ▸ | PTGES | O14684 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4872408 | 0.89 | SCN2A (0.58) | JAK2MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL6027062 | 0.82 | SCN2A (0.65) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL9976067 | 0.82 | SCN2A (0.63) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL6027173 | 0.80 | SCN2A (0.66) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL6026651 | 0.77 | SCN2A (0.73) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL26986686 | 0.76 | SCN2A (0.53) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL6026722 | 0.76 | SCN2A (0.58) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL1624154 | 0.75 | SCN2A (0.49) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL6026384 | 0.75 | TSHR (0.58) | JAK2MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL8370164 | 0.73 | MAPT (0.55) | MAPTALDH1A1MEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326790-B2 | Diphenylisoxazole compounds and hydro isomers thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7220745-B2 | Heterocyclic compounds useful to treat HCV | RIGEL PHARMACEUTICALS (US) | 2007-05-22 | — | — | US | disclosed |
| EP-1641452-A1 | HETEROCYCLIC COMPOUNDS USEFUL TO TREAT HCV | Rigel Pharmaceuticals (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20040254227-A1 | Heterocyclic compounds and hydro isomers thereof | MIDCAP FINANCIAL TRUST | 2004-12-16 | — | — | US | disclosed |
| WO-2004103366-A1 | HETEROCYCLIC COMPOUNDS USEFUL TO TREAT HCV | RIGEL PHARMACEUTICALS (US) | 2004-12-02 | — | — | WO | disclosed |
| US-20040142985-A1 | Heterocyclic compounds useful to treat HCV | RIGEL PHARMACEUTICALS | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142985-A1 | Heterocyclic compounds useful to treat HCV | HAVCR2, PCNA, HCCS | JAK2 206/4885MAPT 4317/4885ALDH1A1 1236/4885 |
| US-20040254227-A1 | Heterocyclic compounds and hydro isomers thereof | HAVCR2, PCNA, HCCS | JAK2 120/4885MAPT 4266/4885ALDH1A1 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.